Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FDMT 4D Molecular Therapeutics	$3.42 +0.6%	$3.68	$2.24 ▼ $28.93	$158.35M	2.89	832,053 shs	819,134 shs
IKT Inhibikase Therapeutics	$2.16 +10.2%	$2.20	$1.12 ▼ $4.20	$160.58M	1.02	230,181 shs	112,002 shs
NBTX Nanobiotix	$3.29 +1.9%	$3.46	$2.76 ▼ $7.51	$155.07M	0.26	15,092 shs	773 shs
PVCT Provectus Biopharmaceuticals	$0.10 +0.4%	$0.10	$0.04 ▼ $0.20	$41.61M	0.59	216,797 shs	50,000 shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FDMT 4D Molecular Therapeutics	+0.59%	+17.53%	-12.98%	-29.77%	-86.22%
IKT Inhibikase Therapeutics	+10.20%	+9.09%	-8.86%	-23.67%	+36.71%
NBTX Nanobiotix	-2.37%	+0.30%	-9.02%	+2.49%	-43.28%
PVCT Provectus Biopharmaceuticals	+2.91%	+1.43%	+1.43%	-16.03%	-49.18%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
FDMT 4D Molecular Therapeutics	2.8021 of 5 stars	4.3	1.0	0.0	0.0	3.5	1.7	0.6
IKT Inhibikase Therapeutics	1.0093 of 5 stars	3.3	0.0	0.0	0.0	0.6	0.0	0.6
NBTX Nanobiotix	1.7149 of 5 stars	3.3	5.0	0.0	0.0	0.0	0.0	0.6
PVCT Provectus Biopharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
FDMT 4D Molecular Therapeutics	2.50	Moderate Buy	$26.71	681.12% Upside
IKT Inhibikase Therapeutics	2.50	Moderate Buy	$6.50	200.93% Upside
NBTX Nanobiotix	2.67	Moderate Buy	$8.00	143.16% Upside
PVCT Provectus Biopharmaceuticals	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest PVCT, FDMT, NBTX, and IKT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/8/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (D-)
4/4/2025	NBTX Nanobiotix	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $8.00
3/28/2025	IKT Inhibikase Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
3/22/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (E+)
3/10/2025	FDMT 4D Molecular Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$42.00 ➝ $40.00
3/7/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (D-)
3/4/2025	FDMT 4D Molecular Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $28.00
3/3/2025	FDMT 4D Molecular Therapeutics	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$39.00 ➝ $35.00
3/3/2025	FDMT 4D Molecular Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$36.00 ➝ $36.00
2/19/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (D-)
2/17/2025	NBTX Nanobiotix	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold

(Data available from 4/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
FDMT 4D Molecular Therapeutics	$37K	4,279.81	N/A	N/A	$7.20 per share	0.48
IKT Inhibikase Therapeutics	$260K	617.61	N/A	N/A	$1.78 per share	1.21
NBTX Nanobiotix	-$11.61M	-13.36	N/A	N/A	($0.04) per share	-82.25
PVCT Provectus Biopharmaceuticals	$560K	74.30	N/A	N/A	($0.02) per share	-4.95

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
FDMT 4D Molecular Therapeutics	-$100.84M	-$2.98	N/A	N/A	N/A	N/A	-28.00%	-26.16%	5/8/2025 (Estimated)
IKT Inhibikase Therapeutics	-$19.03M	-$2.67	N/A	N/A	N/A	N/A	-350.63%	-201.82%	N/A
NBTX Nanobiotix	-$42.97M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	5/20/2025 (Estimated)
PVCT Provectus Biopharmaceuticals	-$3.10M	N/A	0.00	∞	N/A	-418.23%	N/A	-289.35%	5/12/2025 (Estimated)

Latest PVCT, FDMT, NBTX, and IKT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/8/2025	Q1 2025	FDMT 4D Molecular Therapeutics	-$0.84	N/A	N/A	N/A	$0.53 million	N/A
2/28/2025	Q4 2024	FDMT 4D Molecular Therapeutics	-$0.80	-$0.90	-$0.10	-$0.90	$2.28 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
FDMT 4D Molecular Therapeutics	N/A	N/A	N/A	N/A	N/A
IKT Inhibikase Therapeutics	N/A	N/A	N/A	N/A	N/A
NBTX Nanobiotix	N/A	N/A	N/A	N/A	N/A
PVCT Provectus Biopharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
FDMT 4D Molecular Therapeutics	N/A	17.33	17.33
IKT Inhibikase Therapeutics	N/A	0.85	0.85
NBTX Nanobiotix	N/A	1.42	N/A
PVCT Provectus Biopharmaceuticals	N/A	0.12	0.12

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
FDMT 4D Molecular Therapeutics	99.27%
IKT Inhibikase Therapeutics	3.81%
NBTX Nanobiotix	38.81%
PVCT Provectus Biopharmaceuticals	0.05%

Insider Ownership

Company	Insider Ownership
FDMT 4D Molecular Therapeutics	7.30%
IKT Inhibikase Therapeutics	4.59%
NBTX Nanobiotix	3.45%
PVCT Provectus Biopharmaceuticals	12.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
FDMT 4D Molecular Therapeutics	120	46.30 million	42.85 million	Optionable
IKT Inhibikase Therapeutics	6	74.34 million	66.18 million	Not Optionable
NBTX Nanobiotix	100	47.13 million	45.51 million	Not Optionable
PVCT Provectus Biopharmaceuticals	4	420.28 million	366.48 million	Not Optionable

PVCT, FDMT, NBTX, and IKT Headlines

Recent News About These Companies

Provectus announces $3M seed financing round for VisiRose

January 15, 2025 | markets.businessinsider.com

Provectus Biopharmaceuticals Announces Seed Financing for VisiRose, Provectus’s Spinoff Company for Rose Bengal-Based Eye Drugs

January 14, 2025 | markets.businessinsider.com

Provectus Biopharmaceuticals Announces Seed Financing for VisiRose, Provectus's Spinoff Company for Rose Bengal-Based Eye Drugs

January 14, 2025 | globenewswire.com

Provectus launches VisiRose, Provectus’s Founded Entity for pharmaceutical-grade rose bengal sodium-based treatments in ophthalmology

December 13, 2024 | pharmabiz.com

Provectus announces the launch of VisiRose

December 12, 2024 | markets.businessinsider.com

VisiRose Introduces Revolutionary Therapy for Severe Eye Infections

December 11, 2024 | miamiherald.com

Provectus Pharmaceuticals Aligns Leadership with Equity Grants

December 6, 2024 | markets.businessinsider.com

Provectus Pharmaceuticals to Reveal Key 2024 Updates

November 15, 2024 | markets.businessinsider.com

Provectus Biopharmaceuticals, Inc. (PVCT) Q4 2024 Earnings Call Transcript

November 14, 2024 | seekingalpha.com

Provectus Biopharmaceuticals Announces Investor Webinar for Fourth Quarter 2024 Conference Call

October 24, 2024 | manilatimes.net

Provectus Biopharmaceuticals Announces Fourth Quarter 2024 Conference Call

October 10, 2024 | globenewswire.com

Provectus Biopharmaceuticals Announces Poster Presentation of Rose Bengal Sodium for Treatment of Full-Thickness Cutaneous Wounds at SID 2024 Annual Meeting

May 21, 2024 | finance.yahoo.com

Provectus Biopharmaceuticals Announces Eight Presentations of Rose Bengal Photodynamic Antimicrobial Therapy at ARVO 2024 Annual Meeting

May 14, 2024 | finance.yahoo.com

Provectus Biopharmaceuticals Announces Publication of Preclinical Data of Oral Administration of Provectus Rose Bengal for Solid Tumor Cancers

April 18, 2024 | finance.yahoo.com

Provectus Biopharmaceuticals Announces Management Additions and Reiterates Commitment to Shareholder Value Creation

April 16, 2024 | finance.yahoo.com

Provectus Biopharmaceuticals Announces Exclusive Worldwide License Agreement with University of Miami for Photodynamic Antimicrobial Treatment of Different Eye Infections with Rose Bengal Sodium

March 27, 2024 | finance.yahoo.com

Provectus Biopharmaceuticals Announces Notices of Allowance and Award for U.S. Patents of Rose Bengal Sodium in Virology, Pediatric Solid Tumor Cancers, and Vaccines

March 12, 2024 | globenewswire.com

Provectus Biopharmaceuticals Announces Acceptance of Cancer Immunotherapy PV-10 Abstract for HNSCC at AACR 2024 Annual Meeting

March 7, 2024 | globenewswire.com

Provectus Biopharmaceuticals Announces Acceptance of Pharmaceutical-Grade Rose Bengal Sodium Abstract for Poster Presentation at 2024 Society for Investigative Dermatology (SID) Annual Meeting

February 29, 2024 | globenewswire.com

Provectus Biopharmaceuticals, Inc. (PNK:PVCT) Q1 2024 Earnings Call Transcript

February 23, 2024 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PVCT, FDMT, NBTX, and IKT Company Descriptions

4D Molecular Therapeutics NASDAQ:FDMT

$3.42 +0.02 (+0.59%)

Closing price 04/23/2025 04:00 PM Eastern

Extended Trading

$3.46 +0.04 (+1.02%)

As of 04/23/2025 05:20 PM Eastern

4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.

Inhibikase Therapeutics NYSE:IKT

$2.16 +0.20 (+10.20%)

Closing price 04/23/2025 04:00 PM Eastern

Extended Trading

$2.15 -0.01 (-0.46%)

As of 04/23/2025 04:30 PM Eastern

Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.

Nanobiotix NASDAQ:NBTX

$3.29 +0.06 (+1.86%)

Closing price 04/23/2025 02:22 PM Eastern

Extended Trading

$3.35 +0.06 (+1.82%)

As of 04/23/2025 07:50 PM Eastern

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.

Provectus Biopharmaceuticals OTCMKTS:PVCT

$0.10 +0.00 (+0.41%)

As of 04/23/2025 09:32 AM Eastern

Provectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes in the United States. The company's lead molecule is rose bengal sodium (RBS). Its clinical development programs include PV-10 for the treatment of stage III and IV melanoma and different types of liver cancers; PH-10 for the treatment of psoriasis and atopic dermatitis, and skin inflammation; and PV-305 for the treatment of infectious keratitis. It is also developing oral formulations for adult solid tumor cancers, as well as refractory and relapsed pediatric, and other blood cancers comprising leukemias; PV-10 for the treatment of relapsed and refractory pediatric solid tumor cancers; and other formulations for the treatment of cutaneous canine cancers and healing of full-thickness cutaneous wounds. In addition, the company develops oral and intranasal formulations for the treatment of severe acute respiratory syndrome coronavirus 2; gram-positive and gram-negative bacterial infections; oral bacterial infections; and fungal infections, as well as vertebrate development, wound healing, and tissue regrowth. It has collaboration agreement with Bascom Palmer Eye Institute; and University of Miami. The company was formerly known as Provectus Pharmaceuticals, Inc. and changed its name to Provectus Biopharmaceuticals, Inc. in December 2013. Provectus Biopharmaceuticals, Inc. was founded in 2002 and is based in Knoxville, Tennessee.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time